title: Therapeutic Guide for mTOuRing through the Braided Kidney Cancer Genomic River.
abstract: mTORC1 inhibitors were first approved for the use in metastatic kidney cancer. However, observed treatment benefit was highly heterogeneous among patients. Through case-based cancer genomic sequencing of therapeutic outliers, we can begin to appreciate the convergent evolution of given cancer pathways/phenotypes beyond genes in kidney cancer, like a braided river. Clin Cancer Res; 22(10); 2320-2. ©2016 AACRSee related article by Kwiatkowski et al., p. 2445.
authors.affiliation: Department of Medicine, GU Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Martin H
authors.initials: MH
authors.lastname: Voss
authors.affiliation: Department of Medicine, GU Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. hsiehj@mskcc.org.
authors.forename: James J
authors.initials: JJ
authors.lastname: Hsieh
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000378:metabolism; D023281:Genomics / Q000379:methods; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009154:Mutation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases